Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

5042 - Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study)

Date

09 Sep 2017

Session

CNS tumours

Presenters

NOELIA VilariÑo Quintela

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

N. VilariÑo Quintela1, N. Martinez Bosch2, C. Balana3, F. Alameda4, A. Estival3, E. Pineda5, S. Del Barco6, M. Gil7, C. Mesia8, O. Gallego9, C. Carrato10, T. Ribalta11, N. Vidal7, N. Dela Iglesia12, O. Arpi2, J. Capellades1, N. Garcia3, J.M. Velarde13, P. Navarro14, M. Martinez-Garcia1

Author affiliations

  • 1 Medical Oncology, University Hospital del Mar, 8003 - Barcelona/ES
  • 2 Molecular Mechanisms, IMIM-Hospital del Mar, Barcelona/ES
  • 3 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 4 Pathology, University Hospital del Mar, 8003 - Barcelona/ES
  • 5 Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 6 Clinical Oncology, 15Instituto Catalan de Oncologia de Girona, Girona/ES
  • 7 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 8 Medical Oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 9 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 10 Pathology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 11 Pathology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 12 Biology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 13 Biostatistics, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 14 Molecular Mechanisms, IMIM-Hopsital del Mar, Barcelona/ES
More

Resources

Abstract 5042

Background

Gal-1 is a β-galactoside binding protein that plays an important role in cancer progression and has been implicated in resistance to chemotherapy and anti-VEGF therapy. Gal-1 mediates glioma aggressiveness and its expression increases with grade and correlates with worse outcome. Our aim was to evaluate the prognostic significance of Gal-1 in a homogenous cohort of GB.

Methods

GLIOCAT is a multicenter study of newly diagnosed 432 GB patients treated with Stupp regimen. Tissue from 272 patients was used to generate a tissue microarray and Gal-1 expression in cytoplasm (C) and nucleus (N) was analyzed by immunohistochemistry. Results were evaluated by three reviewers and quantified by H-Score. Expression levels were correlated with clinical characteristics, known prognostic factors and response to anti-angiogenic treatment. Preliminary results will be presented at 2017 ASCO, abstract e13526. We will report here the final results.

Results

We defined a cut off for Gal-1 H-Score of ≥ 157 (cytoplasm, C) and ≥123 (nucleus, N). High combined Gal-1 expression significantly correlated with worse OS. No correlation was found with PFS.Table:

330PD

H-ScorenmOS (months) (range)p value
Combined H-Score Low (C 

Conclusions

Gal-1 expression represents an independent prognostic factor for GB patients treated initially with standard therapy and with other therapies at recurrence.

Clinical trial identification

Legal entity responsible for the study

Gliocat group

Funding

Marató TV3 2012

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.